

## **Clinical Oral Investigations**

**Comparative efficacy of medicaments or techniques for pulpotomy of primary molars: a network meta-analysis**

**Running title: network meta-analysis of pulpotomy medicaments or techniques**

Jiehua Guo<sup>1,\*</sup>, Na Zhang<sup>1</sup>, Yuzhao Cheng<sup>1</sup>

<sup>1</sup>Department of oral medicine, Shanxi Provincial People's Hospital, Taiyuan, Shanxi, China

**\*Corresponding author**

Jiehua Guo

Department of oral medicine, Shanxi Provincial People's Hospital, NO.29 The twin towers temple District, Taiyuan, Shanxi, China

Email: dentist0355@163.com

**Table S1.** Detailed search strategies of target databases.**PubMed**

No.	Search Details	Results
20	("Pulpotomy"[MeSH Terms] OR ("Pulpotomy"[Title/Abstract] OR "Pulpotomies"[Title/Abstract] OR "dental drilling"[Title/Abstract])) AND ("ferric sulfate"[Supplementary Concept] OR ("ferric sulfate"[Title/Abstract] OR "polyferric sulfate"[Title/Abstract]) OR ("formocresol"[Supplementary Concept] OR ("formocresol"[Title/Abstract] OR "formaldehyde cresol"[Title/Abstract])) OR ("Sodium Hypochlorite"[MeSH Terms] OR ("Sodium Hypochlorite"[Title/Abstract] OR "Antiformin"[Title/Abstract] OR "Clorox"[Title/Abstract])) OR ("Calcium Hydroxide"[MeSH Terms] OR "Calcium Hydroxide"[Title/Abstract] OR ("MTA"[Title/Abstract] OR ((methods"[MeSH Subheading] OR "methods"[All Fields] OR "mt"[All Fields]) AND "aggregate"[Title/Abstract]) OR "aggregate proroot"[Title/Abstract])) AND ("random*"[All Fields] OR ((allocate"[All Fields] OR "allocated"[All Fields] OR "allocates"[All Fields] OR "allocating"[All Fields] OR "allocation"[All Fields] OR "allocational"[All Fields] OR "allocations"[All Fields] OR "allocative"[All Fields] OR "allocator"[All Fields] OR "allocators"[All Fields]) AND "conceal*"[All Fields]))	267
19	"ferric sulfate"[Supplementary Concept] OR ("ferric sulfate"[Title/Abstract] OR "polyferric sulfate"[Title/Abstract]) OR ("formocresol"[Supplementary Concept] OR ("formocresol"[Title/Abstract] OR "formaldehyde cresol"[Title/Abstract])) OR ("Sodium Hypochlorite"[MeSH Terms] OR ("Sodium Hypochlorite"[Title/Abstract] OR "Antiformin"[Title/Abstract] OR "Clorox"[Title/Abstract])) OR ("Calcium Hydroxide"[MeSH Terms] OR "Calcium Hydroxide"[Title/Abstract] OR ("MTA"[Title/Abstract] OR ((methods"[MeSH Subheading] OR "methods"[All Fields] OR "mt"[All Fields]) AND "aggregate"[Title/Abstract]) OR "aggregate proroot"[Title/Abstract]))	86,702
18	"random*"[All Fields] OR ((allocate"[All Fields] OR "allocated"[All Fields] OR "allocates"[All Fields] OR "allocating"[All Fields] OR "allocation"[All Fields] OR "allocational"[All Fields] OR "allocations"[All Fields] OR "allocative"[All Fields] OR "allocator"[All Fields] OR "allocators"[All Fields]) AND "conceal*"[All Fields])	1,556,94 1
17	"MTA"[Title/Abstract] OR ((methods"[MeSH Subheading] OR "methods"[All Fields] OR "mt"[All Fields]) AND	20,934

	"aggregate"[Title/Abstract]) OR "aggregate proroot"[Title/Abstract]	
16	"mineral trioxide aggregate"[Supplementary Concept]	1,859
15	"Calcium Hydroxide"[MeSH Terms] OR "Calcium Hydroxide"[Title/Abstract]	6,252
14	"calcium hydroxide"[Title/Abstract]	4,315
13	"Calcium Hydroxide"[MeSH Terms]	4,507
12	"Sodium Hypochlorite"[MeSH Terms] OR "Sodium Hypochlorite"[Title/Abstract] OR "Antiformin"[Title/Abstract] OR "Clorox"[Title/Abstract]	8,629
11	"sodium hypochlorite"[Title/Abstract] OR "Antiformin"[Title/Abstract] OR "Clorox"[Title/Abstract]	6,561
10	"Sodium Hypochlorite"[MeSH Terms]	5,081
9	"formocresol"[Supplementary Concept] OR "formocresol"[Title/Abstract] OR "formaldehyde cresol"[Title/Abstract]	595
8	"formocresol"[Title/Abstract] OR "formaldehyde cresol"[Title/Abstract]	560
7	"formocresol"[Supplementary Concept]	271
6	"ferric sulfate"[Supplementary Concept] OR "ferric sulfate"[Title/Abstract] OR "polyferric sulfate"[Title/Abstract]	626
5	"ferric sulfate"[Title/Abstract] OR "polyferric sulfate"[Title/Abstract]	362
4	"ferric sulfate"[Supplementary Concept]	411
3	"Pulpotomy"[MeSH Terms] OR "Pulpotomy"[Title/Abstract] OR "Pulpotomies"[Title/Abstract] OR "dental drilling"[Title/Abstract]	2,084
2	"Pulpotomy"[Title/Abstract] OR "Pulpotomies"[Title/Abstract] OR "dental drilling"[Title/Abstract]	1,402
1	"Pulpotomy"[MeSH Terms]	1,662

### Embase

#No .	Query	Results
#22	#21 AND [embase]/lim	53
#21	#3 AND #19 AND #20	222
#20	random*:ti,ab,kw OR allocation:ti,ab,kw	1843475
#19	#6 OR #9 OR #12 OR #15 OR #18	273028
#18	#16 OR #17	5978
#17	'mineral trioxide aggregate'/exp	1902
#16	'mineral trioxide aggregate':ti,ab,kw OR 'mt aggregate':ti,ab,kw OR mta:ti,ab,kw OR 'aggregate proroot':ti,ab,kw	5849
#15	#13 OR #14	6942

#14	'calcium hydroxide'/exp	6013
#13	'calcium hydroxide':ti,ab,kw	4242
#12	#10 OR #11	10898
#11	'hypochlorite sodium'/exp	9284
#10	'sodium hypochlorite':ti,ab,kw OR antiformin:ti,ab,kw OR clorox:ti,ab,kw	6670
#9	#7 OR #8	682
#8	'formocresol'/exp	574
#7	formocresol:ti,ab,kw OR formacresol:ti,ab,kw OR 'formaldehyde cresol':ti,ab,kw	553
#6	#4 OR #5	864
#5	'ferric sulfate'/exp	722
#4	'ferric sulfate':ti,ab,kw OR 'polyferric sulfate':ti,ab,kw	415
#3	#1 OR #2	1443
#2	'pulpotomy'/exp	493
#1	pulpotomy:ti,ab,kw OR pulpotomies:ti,ab,kw OR 'dental drilling':ti,ab,kw	1362

#### Cochrane Central Registry of Controlled Trials (CENTRAL)

#No .	Search	Hits
#1	(Pulpotomy):ti,ab,kw OR (Pulpotomies):ti,ab,kw OR (dental drilling):ti,ab,kw	740
#2	MeSH descriptor: [Pulpotomy] explode all trees	183
#3	#1 or #2	740
#4	(ferric sulfate):ti,ab,kw OR (polyferric sulfate):ti,ab,kw	300
#5	(formocresol):ti,ab,kw OR (Formaldehyde cresol):ti,ab,kw	163
#6	(Sodium Hypochlorit):ti,ab,kw OR (Antiformin):ti,ab,kw OR (Clorox):ti,ab,kw	9
#7	MeSH descriptor: [Sodium Hypochlorite] explode all trees	481
#8	#6 or #7	486
#9	(Calcium Hydroxide):ti,ab,kw	869
#10	MeSH descriptor: [Saline Solution] explode all trees	150
#11	#9 or #10	1018
#12	(mineral trioxide aggregate):ti,ab,kw OR (MTA):ti,ab,kw OR (MT aggregate):ti,ab,kw OR (aggregate ProRoot):ti,ab,kw	842
#13	#4 or #5 or #8 or #11 or #12	25483
#14	(random*):ti,ab,kw OR (allocation):ti,ab,kw	113120 9
#15	#3 and #13 and #14 in Trials	240

**Table S2. Local consistency model test between different pulpotomy medicaments**

Local consistency model test was evaluated by using node-splitting method, and a P of >0.05 suggested that local consistency assumption was established. For all outcomes, A, B, C, D, E, F, and G represents formocresol, ferric sulphate, sodium hypochlorite, calcium hydroxide, mineral trioxide aggregate, biobentine, and laser, respectively.

**(1) Local inconsistency evaluation for clinical success rate at 6 months.**

. network sidesplit all, tau									
Side	Direct		Indirect		Difference		tau		
	Coef.	Std. Err.	Coef.	Std. Err.	Coef.	Std. Err.	P> z		
A B	<b>-0.1448938</b>	<b>.4885681</b>	<b>-.7227344</b>	<b>.8846618</b>	<b>.5778405</b>	<b>1.044539</b>	<b>0.580</b>	<b>.2454361</b>	
A C	<b>-0.0183985</b>	<b>.6695121</b>	<b>.2638611</b>	<b>1.089181</b>	<b>-.2822596</b>	<b>1.305055</b>	<b>0.829</b>	<b>.2974583</b>	
A D	<b>-2.137115</b>	<b>.9880096</b>	<b>-2.231494</b>	<b>1.420251</b>	<b>.094379</b>	<b>1.7256</b>	<b>0.956</b>	<b>.3061202</b>	
A E	<b>.3064395</b>	<b>.3837214</b>	<b>1.045369</b>	<b>.7474809</b>	<b>-.7389292</b>	<b>.8585123</b>	<b>0.389</b>	<b>.1963843</b>	
A F	<b>1.539784</b>	<b>.923803</b>	<b>.358435</b>	<b>.6147251</b>	<b>1.181349</b>	<b>1.09704</b>	<b>0.282</b>	<b>.1854211</b>	
A G	<b>-1.73e-09</b>	<b>.8659389</b>	<b>.439144</b>	<b>.825372</b>	<b>-.439144</b>	<b>1.196281</b>	<b>0.714</b>	<b>.3261899</b>	
B C	<b>.816718</b>	<b>.6746899</b>	<b>-.4654708</b>	<b>.8994649</b>	<b>1.282189</b>	<b>1.12579</b>	<b>0.255</b>	<b>.1385903</b>	
B D	<b>-.1417319</b>	<b>2.050621</b>	<b>-2.292883</b>	<b>.9881062</b>	<b>2.151152</b>	<b>2.275986</b>	<b>0.345</b>	<b>.2578133</b>	
B E	<b>1.984713</b>	<b>.9482562</b>	<b>.2358832</b>	<b>.5341494</b>	<b>1.748829</b>	<b>1.089549</b>	<b>0.108</b>	<b>1.28e-09</b>	
B G	<b>1.820713</b>	<b>1.638037</b>	<b>.2378627</b>	<b>.7521797</b>	<b>1.58285</b>	<b>1.802476</b>	<b>0.380</b>	<b>.2652432</b>	
C E	<b>.0983934</b>	<b>1.593933</b>	<b>.4743716</b>	<b>.7228101</b>	<b>-.3759782</b>	<b>1.744001</b>	<b>0.829</b>	<b>.3007057</b>	
D E	<b>2.157971</b>	<b>1.241473</b>	<b>3.036317</b>	<b>1.125175</b>	<b>-.8783465</b>	<b>1.677681</b>	<b>0.601</b>	<b>.3213794</b>	
E F	<b>.1561771</b>	<b>.4584218</b>	<b>1.210116</b>	<b>1.268077</b>	<b>-1.053938</b>	<b>1.313019</b>	<b>0.422</b>	<b>.2324784</b>	
E G	<b>-.0695622</b>	<b>.9094762</b>	<b>-.3978202</b>	<b>.8275954</b>	<b>.328258</b>	<b>1.229377</b>	<b>0.789</b>	<b>.33568</b>	
F G	<b>-1.494279</b>	<b>1.38956</b>	<b>-.0229183</b>	<b>.9170031</b>	<b>-1.471361</b>	<b>1.752566</b>	<b>0.401</b>	<b>.2840517</b>	

**(2) Local inconsistency evaluation for clinical success rate at 12 months.**

. network sidesplit all, tau									
Side	Direct		Indirect		Difference		tau		
	Coef.	Std. Err.	Coef.	Std. Err.	Coef.	Std. Err.	P> z		
A B	<b>-.0399655</b>	<b>.4468024</b>	<b>-.9529685</b>	<b>.7738564</b>	<b>.913003</b>	<b>.9003061</b>	<b>0.311</b>	<b>.4421111</b>	
A C	<b>-.2556346</b>	<b>.605124</b>	<b>.3072173</b>	<b>.8927584</b>	<b>-.5628519</b>	<b>1.09552</b>	<b>0.607</b>	<b>.511837</b>	
A D	<b>-1.983862</b>	<b>.7395351</b>	<b>-2.576135</b>	<b>1.410545</b>	<b>.5922733</b>	<b>1.581983</b>	<b>0.708</b>	<b>.5093049</b>	
A E	<b>.4850446</b>	<b>.4183065</b>	<b>1.227591</b>	<b>.8189307</b>	<b>-.742546</b>	<b>.9396481</b>	<b>0.429</b>	<b>.4420701</b>	
A F	<b>1.774631</b>	<b>1.222414</b>	<b>.2987236</b>	<b>.5793112</b>	<b>1.475908</b>	<b>1.352262</b>	<b>0.275</b>	<b>.4579616</b>	
A G	<b>.15666276</b>	<b>.6897223</b>	<b>1.61303</b>	<b>1.740368</b>	<b>-1.456403</b>	<b>1.872089</b>	<b>0.437</b>	<b>.5032362</b>	
B C	<b>.3099784</b>	<b>.5789222</b>	<b>-.1057937</b>	<b>.9666847</b>	<b>.415772</b>	<b>1.117944</b>	<b>0.710</b>	<b>.5085817</b>	
B D	<b>-.4560559</b>	<b>1.662982</b>	<b>-2.233605</b>	<b>.8410855</b>	<b>1.777549</b>	<b>1.914949</b>	<b>0.353</b>	<b>.4742363</b>	
B E	<b>1.341878</b>	<b>.7173711</b>	<b>.5530696</b>	<b>.6822877</b>	<b>.7888085</b>	<b>1.007149</b>	<b>0.434</b>	<b>.4270769</b>	
B G	<b>1.820718</b>	<b>1.692944</b>	<b>.3643106</b>	<b>.7991635</b>	<b>1.456407</b>	<b>1.872082</b>	<b>0.437</b>	<b>.503237</b>	
C E	<b>1.27428</b>	<b>.8639416</b>	<b>.3135455</b>	<b>.7473522</b>	<b>.9607349</b>	<b>1.165363</b>	<b>0.410</b>	<b>.4595949</b>	
D E	<b>2.098725</b>	<b>1.16089</b>	<b>3.178453</b>	<b>.917214</b>	<b>-1.079728</b>	<b>1.517943</b>	<b>0.477</b>	<b>.5138982</b>	
E F	<b>-.1580392</b>	<b>.4454506</b>	<b>1.281838</b>	<b>1.67869</b>	<b>-1.439877</b>	<b>1.72896</b>	<b>0.405</b>	<b>.4695067</b>	

**(3) Local inconsistency evaluation for radiographic success rate at 6 months.**

. network sidesplit all, tau									
Side	Direct		Indirect		Difference		tau		
	Coef.	Std. Err.	Coef.	Std. Err.	Coef.	Std. Err.	P> z		
A B	.0298195	.33974	-1.229361	.6763617	1.25918	.7694598	0.102	9.73e-09	
A C	-.5837717	.4075917	1.469841	.7452409	-2.053613	.8806904	0.020	2.00e-10	
A D	-2.759601	.9497164	-2.014636	1.374156	-.7449651	1.670409	0.656	.0000433	
A E	1.008124	.2896357	1.291833	.6778619	-.2837093	.7481442	0.705	.1091777	
A F	1.460964	.7232467	.4671467	.4020001	.9938168	.8272104	0.230	.0001439	
A G	.0743807	.64381	.7998022	.7771782	-.7254215	1.009206	0.472	.0000555	
B C	.5630904	.4530226	-.4949388	.5824127	1.058029	.7392393	0.152	8.94e-10	
B D	-.142912	2.03435	-2.705304	.9043443	2.562392	2.225989	0.250	9.33e-09	
B E	1.895256	.8906283	1.162384	.417546	.7328723	.9766618	0.453	1.19e-06	
B G	1.820723	1.616419	.4389014	.5988199	1.381821	1.723769	0.423	1.18e-08	
C E	1.376	1.235283	1.100716	.4676795	.2752844	1.309549	0.834	.1338581	
D E	2.492567	1.219854	4.371361	1.047712	-1.878794	1.607819	0.243	.0000611	
E F	-.391641	.2831571	.3471818	1.079906	-.7388228	1.101868	0.503	.1371679	
E G	-.0716263	.9027808	-.9855841	.6314818	.9139578	1.101361	0.407	5.46e-08	
F G	-.8848115	1.177833	-.1211073	.6976137	-.7637043	1.424977	0.592	.1327275	

#### (4) Local inconsistency evaluation for radiographic success rate at 12 months.

. network sidesplit all, tau									
Side	Direct		Indirect		Difference		tau		
	Coef.	Std. Err.	Coef.	Std. Err.	Coef.	Std. Err.	P> z		
A B	.0947586	.3403871	-.5399608	.5166715	.6347195	.6182941	0.305	9.52e-08	
A C	-.6975753	.4016688	.2544287	.5404852	-.952004	.6874748	0.166	3.05e-07	
A D	-2.127108	.5744374	-1.540983	1.133086	-.586125	1.300207	0.652	2.11e-08	
A E	.8928832	.262613	1.459847	.6677192	-.5669637	.7246615	0.434	3.44e-07	
A F	1.335864	.8555848	.7750499	.3811924	.5608141	.9360369	0.549	3.95e-09	
A G	.4666433	.4645329	1.760544	1.64199	-1.293901	1.706436	0.448	1.63e-09	
B C	-.1033611	.3593907	-.6759079	.5978644	.5725467	.6996158	0.413	7.83e-09	
B D	-.9447923	1.12753	-2.287457	.6830956	1.342664	1.374106	0.329	3.02e-10	
B E	1.074163	.5892159	1.06804	.421576	.0061231	.7154298	0.993	5.21e-08	
B G	1.820739	1.616419	.5268073	.5468818	1.293932	1.706423	0.448	1.03e-09	
C E	1.929328	.7063027	1.088458	.4418588	.8408703	.8359243	0.314	1.57e-08	
D E	1.826939	.8127069	3.857	.7106158	-2.030061	1.100443	0.065	5.26e-09	
E F	-.1542849	.2808196	.742836	1.276168	-.8971209	1.319107	0.496	2.04e-06	

**Table S3. Loop inconsistency test of first closed loop.**

Loop inconsistency was evaluated by using node-splitting method, and loop consistency assumption was established if 95% confidence interval (CI) contained zero. A, B, C, D, E, F, and G represents formocresol, ferric sulphate, sodium hypochlorite, calcium hydroxide, mineral trioxide aggregate, biobentine, and laser, respectively, respectively.

**(1)** Loop inconsistency evaluation for clinical success rate at 6 months.

Loop	IF	seIF	z_value	p_value	CI_95	Loop_Heterog_tau2
E-F-G	2.179	1.830	1.191	0.234	(0.00, 5.77)	0.000
A-B-D	2.070	2.296	0.902	0.367	(0.00, 6.57)	0.000
A-B-G	1.870	1.875	0.998	0.318	(0.00, 5.54)	0.000
A-E-F	1.217	1.126	1.081	0.280	(0.00, 3.42)	0.000
A-B-C	1.214	1.062	1.143	0.253	(0.00, 3.30)	0.000
A-B-E	1.125	1.183	0.952	0.341	(0.00, 3.44)	0.000
A-F-G	0.728	2.012	0.362	0.717	(0.00, 4.67)	0.000
A-C-E	0.669	1.815	0.369	0.712	(0.00, 4.23)	0.000
B-C-E	0.582	2.168	0.268	0.788	(0.00, 4.83)	0.000
B-E-G	0.551	2.098	0.263	0.793	(0.00, 4.66)	0.000
A-D-E	0.250	1.583	0.158	0.874	(0.00, 3.35)	0.000
B-D-E	0.220	2.660	0.083	0.934	(0.00, 5.43)	0.000
A-E-G	0.183	1.230	0.149	0.882	(0.00, 2.59)	0.000

**(2)** Loop inconsistency evaluation for clinical success rate at 12 months.


Loop	IF	seIF	z_value	p_value	CI_95	Loop_Heterog_tau2
A-B-G	1.602	1.763	0.909	0.364	(0.00, 5.06)	0.000
A-E-F	1.572	1.310	1.200	0.230	(0.00, 4.14)	0.000
A-B-C	1.132	0.883	1.282	0.200	(0.00, 2.86)	0.000
A-B-E	0.719	0.966	0.745	0.456	(0.00, 2.61)	0.253
B-D-E	0.421	2.143	0.197	0.844	(0.00, 4.62)	0.000
B-C-E	0.410	1.341	0.306	0.760	(0.00, 3.04)	0.000
A-C-E	0.404	1.174	0.344	0.731	(0.00, 2.71)	0.286
A-B-D	0.264	2.158	0.122	0.903	(0.00, 4.49)	0.727
A-D-E	0.049	1.621	0.030	0.976	(0.00, 3.23)	0.707

**(3)** Loop inconsistency evaluation for radiographic success rate at 6 months.

Loop	IF	seIF	z_value	p_value	CI_95	Loop_Heterog_tau2
A-B-D	2.422	2.541	0.953	0.340	(0.00, 7.40)	0.424
A-B-G	1.784	1.798	0.992	0.321	(0.00, 5.31)	0.035
E-F-G	1.728	1.540	1.122	0.262	(0.00, 4.75)	0.000
A-B-C	1.364	0.871	1.566	0.117	(0.00, 3.07)	0.230
A-D-E	1.272	1.572	0.809	0.419	(0.00, 4.35)	0.000
A-E-F	1.037	0.880	1.178	0.239	(0.00, 2.76)	0.000
B-C-E	1.004	2.984	0.336	0.737	(0.00, 6.85)	2.917
A-E-G	0.839	1.145	0.733	0.464	(0.00, 3.08)	0.000
A-C-E	0.819	1.602	0.511	0.609	(0.00, 3.96)	0.000
B-E-G	0.498	2.287	0.218	0.828	(0.00, 4.98)	0.310
A-B-E	0.484	1.129	0.429	0.668	(0.00, 2.70)	0.000
B-D-E	0.409	2.659	0.154	0.878	(0.00, 5.62)	0.000
A-F-G	0.151	1.577	0.096	0.924	(0.00, 3.24)	0.000

(4) Loop inconsistency evaluation for radiographic success rate at 12 months.

Loop	IF	seIF	z_value	p_value	CI_95	Loop_Heterog_tau2
B-D-E	1.603	1.607	0.998	0.318	(0.00, 4.75)	0.000
A-B-G	1.222	1.916	0.638	0.524	(0.00, 4.98)	0.359
A-D-E	1.136	1.176	0.966	0.334	(0.00, 3.44)	0.202
A-B-C	1.058	0.665	1.592	0.111	(0.00, 2.36)	0.000
B-C-E	0.812	1.079	0.753	0.452	(0.00, 2.93)	0.000
A-E-F	0.566	0.945	0.599	0.549	(0.00, 2.42)	0.000
A-C-E	0.191	0.897	0.212	0.832	(0.00, 1.95)	0.000
A-B-E	0.059	0.821	0.072	0.943	(0.00, 1.67)	0.131
A-B-D	0.016	1.807	0.009	0.993	(0.00, 3.56)	0.774



**Figure S1.** Global inconsistency assessment of clinical and radiographic success at 6 and 12 months. In this figures, 1 to 7 represents formocresol, ferric sulphate, sodium hypochlorite, calcium hydroxide, mineral trioxide aggregate, biobentine, and laser, respectively, respectively.